MorphoSys (MOR) News Today €67.80 +0.05 (+0.07%) (As of 07/25/2024 ET) Add Compare Share Share HeadlinesStock AnalysisChartHeadlinesStock AnalysisChartHeadlines All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 November 2021 October 2021 September 2021 August 2021 Time Period May 23, 2024 | marketbeat.comMorphoSys (ETR:MOR) Hits New 1-Year High at $68.20MorphoSys (ETR:MOR) Reaches New 12-Month High at $68.20May 17, 2024 | benzinga.comLatest News for MorphoSys Stock (NASDAQ:MOR)May 16, 2024 | msn.comMorphoSys gains after Novartis discloses all tender offer conditions were metMay 9, 2024 | marketbeat.comMorphoSys (ETR:MOR) Shares Down 0.1% MorphoSys (ETR:MOR) Trading Down 0.1%May 2, 2024 | finance.yahoo.comUPDATE 2-Novartis to buy radiology drug specialist Mariana for $1 billionApril 30, 2024 | seekingalpha.comMorphoSys: Hold Rating Until The Novartis Deal ClosesApril 29, 2024 | msn.comGermany stocks mixed at close of trade; DAX down 0.16%April 28, 2024 | msn.comNew safety risk for MorphoSys drug could complicate Novartis deal - STATApril 28, 2024 | markets.businessinsider.comMorphoSys earnings: here's what Wall Street expectsApril 24, 2024 | finance.yahoo.comMorphoSys To Present New Phase 3 MANIFEST-2 Data on Pelabresib in Myelofibrosis in Oral Presentation at 2024 ASCO Annual MeetingApril 17, 2024 | marketbeat.comMorphoSys (ETR:MOR) Reaches New 12-Month High at $68.00MorphoSys (ETR:MOR) Reaches New 12-Month High at $68.00April 11, 2024 | msn.comGerman biopharma MorphoSys recommends Novartis offer be acceptedApril 11, 2024 | finanznachrichten.deNovartis Pharma AG: Novartis tender offer for MorphoSys AG commencesApril 11, 2024 | finance.yahoo.comNovartis tender offer for MorphoSys AG commencesApril 11, 2024 | msn.comNovartis begins tender offer for cancer-focused MorphoSysApril 11, 2024 | msn.comNovartis commences tender offer for MorphoSysApril 11, 2024 | finance.yahoo.comUPDATE 2-Novartis begins tender offer for cancer-focused MorphoSysApril 4, 2024 | seekingalpha.comNovartis: Higher Guidance, Now A BuyApril 2, 2024 | marketbeat.comMorphoSys (ETR:MOR) Sets New 52-Week High at $67.30MorphoSys (ETR:MOR) Hits New 52-Week High at $67.30March 22, 2024 | markets.businessinsider.comEQS-News: MorphoSys Announces U.S. Antitrust Clearance of Proposed Acquisition by Novartis Under HSR ActMarch 15, 2024 | finance.yahoo.comMorphoSys AG (NASDAQ:MOR) Q4 2023 Earnings Call TranscriptMarch 13, 2024 | markets.businessinsider.comEQS-News: MorphoSys AG Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate UpdateMarch 13, 2024 | benzinga.comMorphoSys: Q4 Earnings InsightsMarch 12, 2024 | msn.comGerman regulators approve Novartis deal to buy drugmaker MorphosysFebruary 15, 2024 | finance.yahoo.comWhat Makes MorphoSys AG Unsponsored ADR (MOR) a Strong Momentum Stock: Buy Now?February 8, 2024 | finance.yahoo.comBiotech Stock Roundup: GILD, AMGN & BMY's Q4 Results, MOR Up on NVS Deal & MoreFebruary 7, 2024 | realmoney.thestreet.comMorphoSys just downgraded at JMP Securities, here's whyFebruary 6, 2024 | finance.yahoo.comNovartis (NVS) to Buy MorphoSys & Add Late-Stage Oncology DrugFebruary 6, 2024 | seekingalpha.comNovartis And MorphoSys Are A Perfect MatchFebruary 5, 2024 | finance.yahoo.comNovartis to strengthen oncology pipeline with agreement to acquire MorphoSys AG for EUR 68 per share or an aggregate of EUR 2.7bn in cashFebruary 5, 2024 | finance.yahoo.comUPDATE 1-Novartis to acquire cancer drug developer MorphoSys for $2.9 blnFebruary 3, 2024 | morningstar.comMorphoSys AG ADR MORJanuary 31, 2024 | markets.businessinsider.comDAX Edges Higher As Investors Await GDP DataJanuary 30, 2024 | marketwatch.comUS Futures Flat, European Stocks Slightly Down Ahead of Central Bank DecisionsJanuary 30, 2024 | markets.businessinsider.comEuropean Shares Slightly Higher; Flash Eurozone GDP Data AwaitedJanuary 30, 2024 | msn.comMorphoSys expects 2024 Monjuvi U.S. net product sales in $80M - $95M rangeJanuary 30, 2024 | finance.yahoo.comMorphoSys Reports Preliminary 2023 Monjuvi U.S. Net Product Sales and Gross Margin, Provides 2024 Financial Guidance and Reduces Financial LiabilityJanuary 30, 2024 | finance.yahoo.comMorphoSys Reports Preliminary 2023 Monjuvi U.S. Net Product Sales and Gross Margin, Provides 2024 Financial Guidance and Reduces Financial LiabilityJanuary 18, 2024 | seekingalpha.comMorphoSys: Positive Pelabresib Data Finally Unlocking UpsideJanuary 8, 2024 | markets.businessinsider.comEQS-News: MorphoSys to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceJanuary 8, 2024 | finance.yahoo.comMorphoSys to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceDecember 18, 2023 | finance.yahoo.comOptimistic Investors Push MorphoSys AG (ETR:MOR) Shares Up 48% But Growth Is LackingDecember 14, 2023 | markets.businessinsider.comMorphoSys To Issue 3.423 Mln New Shares At EUR 30/shrDecember 14, 2023 | marketwatch.comMorphoSys Shares Fall After Raising Funds to Accelerate Drug Launch, TrialsDecember 13, 2023 | markets.businessinsider.comEQS-Adhoc: Ad hoc: MorphoSys AG Launches Cash Capital Increase by way of Accelerated Bookbuilding ProcessDecember 12, 2023 | markets.businessinsider.comBuy Rating on Morphosys Ag Backed by Pelabresib’s Breakthrough Efficacy in Myelofibrosis TreatmentDecember 11, 2023 | markets.businessinsider.comBuy Rating on Morphosys Ag Backed by Strong MANIFEST-2 Trial Results and FDA Approval PotentialDecember 11, 2023 | msn.comMorphoSys climbs after late-stage data for blood cancer therapyDecember 11, 2023 | markets.businessinsider.comMorphoSys : Pelabresib Improves All Four Hallmarks Of Myelofibrosis In Phase 3 StudyNovember 27, 2023 | msn.comMorphosys AG - ADR (MOR) Price Target Increased by 86.05% to 16.88 Get MorphoSys News Delivered to You Automatically Sign up to receive the latest news and ratings for MOR and its competitors with MarketBeat's FREE daily newsletter. Email Address NEW AI developed by trader who won 1,129% (in 2 days) (Ad)Earlier this year one legendary trader captured a 1,129% win (in just 2 days) ... LIVE in front of thousands of Americans... Click here to see how >>> MOR Media Mentions By Week MOR Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. MOR News Sentiment▼0.000.61▲Average Medical News Sentiment MOR News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. MOR Articles This Week▼01▲MOR Articles Average Week Get MorphoSys News Delivered to You Automatically Sign up to receive the latest news and ratings for MOR and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Medigene News Today Genfit News Today Carl Zeiss Meditec News Today Gerresheimer News Today Evotec News Today CompuGroup Medical SE & Co. KGaA News Today Stratec News Today Drägerwerk AG & Co. KGaA News Today Fielmann Group News Today Fresenius SE & Co. KGaA News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (ETR:MOR) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredFormer Hedge Fund Manager Issues Crash PredictionOur No. 1 stock for the rare "millionaire window" opening NOW According to Wall Street legend Whitney Tilso...Stansberry Research | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MorphoSys AG Please log in to your account or sign up in order to add this asset to your watchlist. Share MorphoSys With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free MOR Stock Alerts